Is ABCL or ABUS more undervalued in 2026?

CirclFi compares AbCellera Biologics Inc. (ABCL) and Arbutus Biopharma Corporation (ABUS) using 13 institutional-grade valuation models. ABCL has a Quality of Company score of 7.3/10 while ABUS scores 7.0/10.

Which is a better buy — ABCL or ABUS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ABCL and ABUS valuations compare?

ABCL at $5.73 and ABUS at $4.60 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ABCL vs ABUS Valuation Comparison 2026 — Intrinsic Value Analysis

ABCL

Biotechnology

AbCellera Biologics Inc.

Quality

7.3

out of 10

Value Trap

SAFE

Price

$5.73

Last close

Models

10/13

Active

ABUS

Biotechnology

Arbutus Biopharma Corporation

Quality

7.0

out of 10

Value Trap

SAFE

Price

$4.60

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	ABCL Fair Value	ABCL Upside	ABUS Fair Value	ABUS Upside
Bayesian DCF	Intrinsic	$3.68	-35.8%	$1.29	-72.0%
Earnings Power Value	Intrinsic	$1.35	-69.6%	—	—
First Chicago	Scenario	$0.46	-91.0%	$4.54	+2.2%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ABCL vs ABUS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ABCL vs ABUS — Which Stock Is More Undervalued?

ABCL scores higher with a 7.3/10 quality rating vs ABUS's 7.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing AbCellera Biologics Inc. (ABCL) and Arbutus Biopharma Corporation (ABUS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ABCL currently trades at $5.73 with a QOC of 7.3/10, while ABUS trades at $4.60 with a QOC of 7.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).